Introduction
Metabolite analysis is important for drug development. At present, research on metabolites is limited to qualitative analysis. 1 The complex composition of biological fluids and low contents make the isolation and the purification of metabolites quite difficult.
Hence, the quantification of metabolites is often impracticable. Fundamentally, kinetic research usually pays more attention to the variation in the trends of drugs, other than the absolute quantity. This paper proposes a relative quantification method for the elimination kinetics of metabolites in urine samples without the separation of pure compounds.
Aconitum shows an excellent effect against rheumatosis and rheumatoid arthritis, and some other inflammations in clinical practice. 2 Aconitine is the major toxic and bioactive component of Aconitum carmichaeli Debx. Its therapeutic dose, toxic dose and lethal dose are very close, which brings challenges to safe use as medication. In addition, since aconitum alkaloids are very unstable and decomposed fast in the human body, 3 metabolite studies are helpful to understand the medication safety, toxification and detoxification mechanism. Earlier publications have described methods for aconitine determination in biological samples, [4] [5] [6] [7] [8] [9] [10] and the identification of metabolites. [11] [12] [13] This paper reports on a pharmacokinetics study of aconitine metabolite in rat urine after oral administration for the first time, using a simple and selective liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.
Experimental

Chemicals and materials
Aconitine and lappaconitine (purity > 98.0%) were purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Acetonitrile (Fisher Co., USA) and methanol (Merck, Germany) were of HPLC grade. All other reagents were of analytical grade. Double-distilled water was used throughout the study.
Instrumentation and analytical conditions
The LC-MS/MS system consisted of an Agilent 1200 series liquid chromatograph and a triple-quadrupole mass spectrometer (API 4000, Applied Biosystems, Foster City, CA) equipped with electrospray ionization (ESI) source. Data acquisition and processing were performed using Analyst 1.4.2 software.
Chromatographic separation was achieved on a Kromasil C18 column (150 × 4.6 mm, 5 μm) maintained at 40 C. The mobile phase consisted of acetonitrile-water-formic acid (80:20:1, v/v/v) with at a flow rate of 0.45 mL/min, and the injection volume was 10 μL.
The electrospray ion source was operated in the positive ion mode. The ion spray voltage was set to 4500 kV, and the entrance potential was 10 V. The ion source temperature was set at 600 C. Nitrogen was used as the nebulizer gas (55 psi), auxiliary gas (65 psi) and curtain gas (25 psi). A selected reaction monitoring (SRM) mode was employed for quantification. The precursor-to-product ion pairs were m/z 632→572 for 16-O-demethylaconitine and m/z 585→162 for lappaconitine (IS).
Preparation of calibration standards and QC samples
An aliquot of 1 mL mixed urine 24 h after the administration of aconitine was added with 4 mL acetonitrile/methanol (3:1, v/v). The mixture was vortex-mixed for 2 min and centrifuged at 10000g for 5 min. The supernatant was separated out and blown to dryness under a gentle stream of nitrogen at 40 C. The residue was reconstituted in 250 μL of the mobile phase as the standard stock solution of metabolites, presuming a concentration of 2c. The stock solution was then serially diluted with methanol to obtain working solutions at concentrations of
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A sensitive and rapid high-performance liquid chromatographic-tandem mass spectrometric (HPLC-MS/MS) method was developed for the quantitation of the major metabolite of aconitine, 16-O-demethylaconitine, lappaconitine as the internal standard in rat urine. Urine samples were precipitated with acetonitrile/methanol (3:1, v/v). Chromatographic separation was achieved on a Kromasil C18 analytical column. Detection was performed by a selective reaction monitoring (SRM) mode via an electrospray ionization (ESI) source operating in the positive ionization mode. The analytical method was validated in terms of specificity, precision, accuracy, extraction recovery. The intra-and inter-day precisions were less than 11.7%, and the accuracy was less than 14.0% for the analyte. The validated method has been applied to a pharmacokinetic study of 16-O-demethylaconitine in rats, following oral administration of aconitine. Then 100 μL of the working solution was added to 200 μL of blank rat urine, vortex-mixed for 30 s. The concentration levels of metabolites in urine ranged from 0.02c to 1.0c. Quality control (QC) samples were prepared in a similar manner at low, medium and high levels (0.05c, 0.20c, 0.80c). All of the spiked urine samples were then treated according to the samplepreparation procedure.
Sample preparation
A 200-μL volume of urine sample was pipetted into an Eppendorf tube with 100 μL of the internal standard solution, 100 μL of methanol and 600 μL of acetonitrile. This mixture was vortex-mixed for 2 min, and centrifuged at 10000g for 5 min. The supernatant was separated out and blown to dryness under a gentle stream of nitrogen at 40 C. Then, the residue was reconstituted in 100 μL of the mobile phase and mixed to make final testing samples. A 10-μL aliquot of the solution was injected into the LC-MS/MS system for analysis.
Method validation
The method was validated according to the currently accepted USA Food and Drug Administration (FDA) bioanalytical method validation guidance. The method for linearity was evaluated by analyzing calibration standards in duplicate at each concentration level over three consecutive days. The accuracy and the precision were assessed by analyzing QC samples in six replicates at three concentration levels on three validation days. The extraction recovery was evaluated at three concentration levels and for the IS at one concentration level by comparing the peak areas of the analyte obtained from six urine samples with the analyte spiked before and after extraction. The matrix effect was evaluated by comparing the peak areas of the analyte obtained from six urine samples with the analyte spiked after extraction, at three concentration levels, to those for the neat standard solutions at the same concentrations. The stability of 16-O-demethylaconitine and IS in rat urine at low and high concentration levels was evaluated under a variety of storage and process conditions.
Pharmacokinetic application
Six Sprague-Dawley rats weighing 220 -250 g were fasted for 12 h. Each rat was administered an oral dose of 0.5 mg/kg aconitine suspended in an aqueous solution containing 0.5% carboxymethyl cellulose sodium. Urine samples were collected before drug administration (0 h), and subsequently at 2, 4, 6, 8, 12 and 24 h following administration. After the accurate volume was measured, the samples were stored at -70 C until analysis.
Results and Discussion
Method development
Different mobile phases consisting of methanol-water or acetonitrile-water were attempted. The selected mobile phase was composed of 20% water (containing 5% formic acid) and 80% acetonitrile, and provided a high mass spectral signal, low background noise and proper retention time.
Comparing with the blank rat urine, we found the ion at m/z 632 at 2.01 min in the urine samples after the administration of aconitine. Its MS 2 spectrum displayed the fragment ion at m/z 572, and was identified as 16-O-demethylaconitine by referring to the literature. 12 
Method validation
Six different lots of blank urine without analytes or internal standards were extracted and analyzed for evaluating the selectivity of this method. No interference peak appeared at the retention times of 16-O-demethylaconitine and IS (Fig. 1) .
The calibration curve showed good linearity over the concentration range of 0.02c -1.0c with a correlation coefficient (R 2 ) of 0.9945. The LLOQs was 0.02c ± 0.003c. Table 1 presents the precision and accuracy for the analyte by analyzing QC samples. The intra-and inter-day precision was less than 11.7%, and the accuracy was less than 14.0%. The mean extraction recoveries (n = 6) for 16-O-demethylaconitine were 77.8 ± 5.7, 80.8 ± 7.3 and 84.1 ± 8.2% at concentrations of 0.02c, 0.05c, 0.20c and 0.80c, respectively. The mean recovery of the IS was 85.8 ± 7.6%. In addition, the matrix effect assessed by spiking samples post-processing were between 85 and 115% from spiked injection solvent, which indicated that the co-eluting matrix components had little or no effect on the ionization of the analyte and the IS (90.6 ± 10.1%).
The stability study showed that 16-O-demethylaconitine was stable in urine at room temperature (25 C) for 4 h (RE < 11.5%), at -70 C for 15 days (RE < 13.1%) and after three freeze-thaw Not required 87.3 ± 7.5 87.5 ± 5.9 108.3 ± 9.3 cycles (RE < 5.4%). The analyte was also shown to be stable after reconstitution at 25 C for 24 h (RE < 10.2%).
Applications to pharmacokinetic study
The validated method was applied to a pharmacokinetic study of 16-O-demethylaconitine after an oral administration of aconitine at a dose of 0.5 mg/kg to six rats. The mean urine concentrations of 16-O-demethylaconitine versus time profile are presented in Fig. 2 .
The disposition model of the metabolite and the drug in vivo is shown in Fig. 3 (D0 was dosage; ka, km and ke were the absorption rate constant of the drug, production rate constant and excretion rate constant of the metabolite, respectively). The profile of the urine concentration-time curves of the metabolite depends on which of km and ke is the rate-limiting factor.
km << ke: the metabolite would be excreted promptly shortly after its production; namely, the production is the rate-limiting factor. The elimination rate of the metabolite is close to its production rate. The elimination of the metabolite could reflect the elimination of the drug in direct proportion, as the first situation in Fig. 3 
